A test that detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, University of Toronto researchers say.
Immunotherapy can shrink tumours and prolong survival for patients for whom other treatments have failed. But it only helps about 20 to 30 per cent of patients and so far, clinicians have been unable to predict who will benefit…..
